TIBBIYAH ANNOUNCES HALF YEAR 2026 RESULTS

- Achieved revenue of ⃁ 312.7 million in H1 2026, largely in line with H1 2025 (-0.5%)
- Grew EBITDA to ⃁ 9.8 million, a ⃁ 4.5 million increase YoY, with operating profit up ⃁ 3.8 million YoY to ⃁ 4.9 million
- Gross profit reached ⃁ 71.6 million, compared to ⃁ 69.5 million for the same period last year, up 3.1% YoY, with gross margin expanding 80bps to 22.9%
- Net loss attributable to equity holders narrowed to ⃁ 18.8 million, an improvement of ⃁ 5.5 million compared to a net loss of ⃁ 24.3 million for the same period last year.

Riyadh, Saudi Arabia, 23 August 2026: Arabian International Healthcare Holding Company ("Tibbiyah" or the "Company", 9530 on the Saudi Exchange's Nomu - Parallel Market), a leading integrated healthcare solutions provider in Saudi Arabia, announced its financial results for the six-month period ended 30 June 2026 (H1 2026). The Company operates across two core segments: Medical Equipment (FMS) and Medical Supplies (Premma & Al-Hammad).

The Company reported revenue of ⃁ 312.7 million, largely in line with H1 2025. Medical Supplies revenue grew 7.6% year-on-year (YoY), due to the strong overall performance across the segment, offsetting a decline in Medical Equipment revenue, highlighting the strength of the Company's diversified portfolio. The Company also delivered a sharp improvement in profitability, with operating profit up ⃁ 3.8 million YoY to ⃁ 4.9 million, and a narrower net loss attributable to equity holders of ⃁ 18.8 million, compared to a net loss of ⃁ 24.3 million for the same period last year.

Mohammad Mostafa, Chief Executive Officer, stated:

"H1 2026 marked tangible progress in how we are operating Tibbiyah. We continued to raise execution standards across our core businesses, with improved margin performance and a stronger contribution from our Medical Supplies platform as we completed the full integration of Al-Hammad. At the same time, we continued to sharpen our portfolio and focus the business around areas where Tibbiyah has the capabilities and market position to create sustainable value.

Looking ahead, we have launched a new strategy that will guide Tibbiyah's next phase of growth and efficiency. Across the organization, we are focused on strengthening the business and positioning Tibbiyah to capture the opportunities emerging across Saudi Arabia's evolving healthcare landscape."

FINANCIAL REVIEW

Revenue of ⃁ 312.7 million in H1 2026 was in line compared to H1 2025. Medical Supplies revenue grew 7.6% YoY to ⃁ 176.4 million, due to strong overall performance across the segment, offsetting a 9.3% YoY decline in Medical Equipment revenue to ⃁ 136.3 million, highlighting the strength of the Company's diversified portfolio.

Gross profit reached ⃁ 71.6 million in H1 2026, compared to ⃁ 69.5 million for the same period last year, up 3.1% YoY. Gross margin expanded 80bps to 22.9% from 22.1%, reflecting better cost management and the product mix, as the business continues to diversify its revenue base across Medical Equipment and Medical Supplies. Margin improvement was particularly notable in Medical Supplies, up approximately 114bps to 21.3%, with Medical Equipment also improving, up 70bps to 25.0%.

Operating profit increased to ⃁ 4.9 million from ⃁ 1.0 million in H1 2025, supported by higher gross profit, lower selling and distribution expenses and a ⃁ 0.4 million net reversal of expected credit losses on trade receivables, compared with a ⃁ 1.7 million impairment charge in the prior-year period. These improvements were partially offset by higher general and administrative expenses.

Net Loss attributable to equity holders of ⃁ 18.8 million in H1 2026, an improvement of ⃁ 5.5 million compared to a net loss of ⃁ 24.3 million in H1 2025. The improvement in attributable net loss also reflected the absence of the ⃁ 2.4 million net loss from discontinued operations and the non-controlling interest recorded in H1 2025, partially offset by higher net finance costs primarily due to the implementation of factoring services for improved cash flow management.

Operating cash flow was an outflow of ⃁ 47.6 million in H1 2026, compared to a net outflow of cash of ⃁ 97.4 million for the same period last year. The improvement was primarily driven by stronger working-capital performance, including improved collection of trade receivables and lower inventory balances, partially offset by reductions in trade payables and accrued liabilities.

Cash and cash equivalents increased to ⃁ 20.5 million as of 30 June 2026, compared with ⃁ 4.9 million at 31 December 2025, reflecting a net cash increase of ⃁ 15.6 million during the period.

Total borrowings stood at ⃁ 352.0 million at 30 June 2026, a decrease of ⃁ 121.0 million, or 25.6%, compared with H1 2025, reflecting deleveraging actions undertaken over the past year. During H1 2026, the Company continued to rebalance its funding mix, including ⃁ 85.5 million of new short-term financing alongside ⃁ 46.0 million of repayments of loans from the ultimate parent company.

SEGMENT REVIEW

Medical Supplies (Premma & Al-Hammad) revenue reached ⃁ 176.4 million in H1 2026, compared to ⃁ 164.0 million for the same period last year, up 7.6% year-on-year, primarily driven by strong overall performance across the segment. Gross margin expanded approximately 114bps to 21.3%, compared to 20.2% for the same period last year, driven by product mix and portfolio enhancement during the period. The segment narrowed its net loss to ⃁ 5.7 million losses in H1 2026, compared to a net loss of ⃁ 11.5 million for the same period last year, reflecting both the improvement in gross profit and a reversal of expected credit loss provisions on trade receivables, compared to an impairment charge recorded in the same period last year.

Medical Equipment (FMS) revenue reached ⃁ 136.3 million in H1 2026, compared to ⃁ 150.2 million for the same period last year, down 9.3% YoY. Gross margin expanded 70bps to 25.0%, compared to 24.3% for the same period last year, driven by effective cost management and product mix. The segment reported a net loss of ⃁ 0.7 million in H1 2026, compared to net income of ⃁ 1.1 million for the same period last year, primarily reflecting the decline in gross profit from the lower revenue base.

PROGRESS ON STRATEGIC INITIATIVES:

Nephroplus (Renal Care Services) In November 2025, Tibbiyah signed a conditional share purchase agreement to acquire a 49% stake in Nephrocare Health Services Saudi Arabia Company, as part of its partnership with NephroPlus, an India-based dialysis clinic network. During H1 2026, the joint venture achieved key operational milestones, including launching its first dialysis clinic at Riyadh Hospital, commencing patient treatments, and obtaining home regulatory licenses. The JV also is progressing in an Expression of Interest (EOI) for the Kingdom's national dialysis services privatization project, supporting its commercialization plans and long-term growth in Saudi Arabia's renal care market.

Genalive JV (Genomic & Testing Laboratory) The Company continues to progress contract signings under the NUPCO genomics tender awarded in March 2025. Volume ramp-up has been slower than initially anticipated; management expects activation to accelerate in the second half of 2026, alongside a broader push to expand commercial activity in the private sector.

Summary Financials (for the period ended 30 June 2026)

BALANCE SHEET (⃁ million)	30 June 2026	31 December 2025
Current Assets	1,012.6	1,197.1
Non-Current Assets	132.8	135.5
Total Assets	**1,145.4**	**1,332.6**
Current Liabilities	695.0	813.6
Non-Current Liabilities	104.1	153.8
Total Liabilities	**799.1**	**967.4**
Total Equity	**346.3**	**365.2**
Total Liabilities and Shareholder Equity	**1,145.4**	**1,332.6**

INCOME STATEMENT (⃁ million)	H1 2026	H1 2025
Revenue	312.7	314.2
Cost of revenue	241.1	244.7
Gross Profit	71.6	69.5
Selling and marketing expenses	40.5	42.6
General and administrative expenses	27.1	22.3
(Reversal)/ impairment loss on trade receivable	(0.4)	1.7
Other income	6.5	5.5
Other expense	2.7	3.9
Share of (loss) / profit of joint venture	(3.4)	(3.4)
Operating Profit	4.9	1.0
Finance charges	18.9	17.9
Finance income	1.2	1.0
(Loss) / Profit Before Zakat	**(12.8)**	**(15.9)**
Zakat	6.0	6.0
(Loss) / Profit From Continuing Operations	**(18.8)**	**(21.9)**
Loss from discontinued operations	-	(4.7)
Non-controlling interests of discontinued operations	-	2.3
(Loss) / Profit Attributable to Equity Holders	**(18.8)**	**(24.3)**
Loss per share	(0.95)	(1.23)

CASH FLOW STATEMENT (⃁ million)	H1 2026	H1 2025
Net cash from (used in) operating activities	**(47.6)**	**(97.4)**
Net cash from (used in) investing activities	**25.7**	**3.8**
Net cash from (used in) financing activities	**37.5**	**111.7**
Cash and cash equivalents at the beginning of the period	**4.9**	**80.6**
Cash and cash equivalents at the end of the period	**20.5**	**98.7**

-Ends-

ABOUT TIBBIYAH

TIBBIYAH is a diversified healthcare holding Company founded in 2013 by Al Faisaliah Group to bring all its subsidiaries working in the healthcare sector under one umbrella. With 50 years of leadership supporting Saudi healthcare service providers improve the lives of Saudi Arabia's population, TIBBIYAH continues to build on its enviable track-record of providing state-of-the-art fully integrated healthcare solutions and turnkey projects, including mega healthcare developments in Saudi Arabia.

TIBBIYAH has two core reporting segments: Medical Equipment, comprising 100% owned Al Faisaliah Medical Systems Company (FMS), and Medical Supplies, comprising 100% owned International Healthcare Supplies Company (Premma) and Al-Hammad Medical Services Co. (Al-Hammad). Beyond its core segments, the Company holds a 50:50 joint venture in Philips Healthcare Saudi Arabia Company and maintains a health-tech vertical including a 50:50 joint venture with BGI Almanahil Health for Medical Services (Genalive) and a 49% stake in Nephrocare Health Services Saudi Arabia Company.

For more information, please visit us on: https://www.tibbiyah.com/